ADCT — ADC Therapeutics SA Share News
0.000.00%
Last trade - 00:00- $138.64m
- $327.99m
- $81.36m
Brief: ADC Therapeutics Announces Pricing Of Underwritten Offering
Brief: Adc Therapeutics SA - SOBI Expects To Commence Launching Zynlonta Upon Completion Of The Marketing Authorization Transfer
U.S. STOCKS ON THE MOVE-Tesla, Nike, Zynerba Pharmaceuticals
U.S. STOCKS ON THE MOVE-Tesla, Nike, Starbucks, Core Scientific
ADC Therapeutics SA reports results for the quarter ended in September - Earnings Summary
Brief: ADC Therapeutics Says Initial Safety Run‐In Results From Lotis-5 Phase 3 Trial Demonstrate ORR Of 75% & 40% CR Rate With No New Safety Signals
Brief: ADC Therapeutics Files For Stock Shelf Of Up To 1.3 Million Common Shares By Selling Stockholders - SEC Filing
Brief: ADC Therapeutics SA Files For Resale Of Up To 4.4 Million Common Shares By Selling Shareholders - SEC Filing
ADC Therapeutics SA reports results for the quarter ended in June - Earnings Summary
Brief: ADC Therapeutics Doses First Patient In Phase 1B Clinical Trial Of ADCT-601
Brief: ADC Therapeutics Announces First Patient Dosed In Phase 2 Clinical Trial Of Zynlonta® (Loncastuximab Tesirine-Lpyl) In Combination With Rituximab In First-Line Diffuse Large B-Cell Lymphoma
NYSE ORDER IMBALANCE 263852.0 SHARES ON BUY SIDE
Brief: ADC Therapeutics Doses First Patient In Phase 1B Clinical Trial Of Zynlonta In Combination With Other Anti-Cancer Agents
Brief: ADC Therapeutics Announces Results From Pivotal Phase 2 Clinical Trial Of Camidanlumab Tesirine In Relapsed Or Refractory Hodgkin Lymphoma
ADC Therapeutics falls on CEO transition
ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary
ADC Therapeutics SA expected to post a loss of 70 cents a share - Earnings Preview
ADC Therapeutics SA expected to post a loss of 70 cents a share - Earnings Preview
ADC Therapeutics SA reports results for the quarter ended in December - Earnings Summary